Startups
Citigate Dewe Rogerson
Edit

Citigate Dewe Rogerson

http://www.citigatedewerogerson.com/
Last activity: 27.02.2026
Active
Categories: B2CBusinessCorporateFinTechFirmGovTechMediaMessangerPublicResearch
Citigate Dewe Rogerson is a leading international communications firm delivering financial, investor relations, public policy, consumer, corporate and digital consultancy.

Our mission is to ensure that our clients engage to best possible effect with all relevant stakeholders across capital markets, government, business and consumers.

Based in London, our global communications consultancy provides a seamless reach across the UK, Continental Europe, MENA and Asia Pacific.

Our business is structured across all major industrial sectors, providing media relations, investor relations, crisis communications, research, public policy, litigation support, creative consumer campaigns and digital expertise.

We are acknowledged as a leader in IPOs and M&A advisory, with a long track record spanning the full spectrum of financial, corporate and investor communications.
Mentions
145

Overview

Location
United Kingdom, England, Westminster
Employees
201-500
Founded date
1987

Mentions in press and media 145

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Sep 18, 2025Interim Report and Unaudited Condensed Consolidated Interim Financial StatementsInterim Report and Unaudited Condensed Consolidated Interim Financial Statements Thu, Sep 18, 2025 08:00 CET Report this content Castelnau Group Limited (the “Group” or “Company”) Interim Report and Unaudited Condensed Consolidated Interim ...
Jun 19, 2025Transgene finalise la sélection initiale de patients pour la partie Phase II de l’essai avec TG4050 dans le cancer de la tête et du cou opérable100 % de survie sans récidive après au moins deux ans de suivi des patients de la partie Phase I de l’essai – preuve de principe clinique démontrée pour TG4050 La randomisation des patients devrait être finalisée d’ici la fin de l’année 202...
Apr 23, 2025Transgene communiquera, dans une présentation orale rapide, de nouvelles données de Phase I du vaccin thérapeutique individualisé TG4050 à l’ASCO 2025Strasbourg, France – Le 23 avril 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce que les données de son étud...
Mar 28, 2025ARGAN and 4MURS inaugurated a new Aut0nom® for 9,500 sq.m in MetzPress release – Neuilly-sur-Seine, Friday, March 28, 2025 – 8.00 am ARGAN and 4MURS inaugurated a new Aut0nom® for 9,500 sq.m in Metz In the presence of Christophe Ranchoup (CEO of 4MURS), François Henrion (Augny’s Mayor) and Cedric Gouth (...
Mar 26, 2025ARGAN delivered a 30,000 sq.m Aut0nom® warehouse for DIMOLOG in the South of RennesPress release – Neuilly-sur-Seine, Wednesday, March 26, 2025 – 17.45 am ARGAN delivered a 30,000 sq.m Aut0nom® warehouse for DIMOLOG in the South of Rennes ARGAN is confirming the ongoing momentum of its development plan with the delivery o...
Mar 21, 2025ARGAN’S COMBINED GENERAL ASSEMBLY OF MARCH 20, 2025Press release – Neuilly-sur-Seine, Friday, March 21, 2025 – 8.00 am ARGAN’s Combined General Assembly of March 20, 2025 Accelerated development plan for 2025-2026: investments up +30% 2024 dividend up +5% (at €3.30/share) with scrip dividen...
Mar 12, 2025ARGAN: 2024 UNIVERSAL REGISTRATION DOCUMENT MADE AVAILABLE IN ENGLISHPress release – Neuilly-sur-Seine, Wednesday, March 12, 2025 – 5.45pm 2024 Universal Registration Document made available in English ARGAN informs the public that the 2024 Universal Registration Document, previously filed in French on Frida...
Feb 27, 2025ARGAN : MODALITÉS DE MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES À L’ASSEMBLÉE GÉNÉRALE MIXTE DU 20 MARS 2025Communiqué de presse – Neuilly-sur-Seine, jeudi 27 février 2025 - 17h45 Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 20 mars 2025 Les actionnaires de la société ARGAN sont invités à participer ...
Jan 21, 2025Transgene participera à la conférence investisseurs Biomed ForumStrasbourg (France), le 21 janvier 2025, 17 h 45 CET – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce aujourd'hui la partic...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Citigate Dewe Rogerson

When was Citigate Dewe Rogerson founded?

Citigate Dewe Rogerson was founded in 1987.

What has the press written about Citigate Dewe Rogerson?

Parsers VC has collected 145 articles mentioning Citigate Dewe Rogerson, among them “Interim Report and Unaudited Condensed Consolidated Interim Financial Statements” (Sep 18, 2025) and “Transgene finalise la sélection initiale de patients pour la partie Phase II de l’essai avec TG4050 dans le cancer de la tête et du cou opérable” (Jun 19, 2025).

Is Citigate Dewe Rogerson still active?

Yes, Citigate Dewe Rogerson is active; its latest activity on Parsers VC dates from Feb 27, 2026.